Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02722668 · OUTCOME

Incidence of Acute GVHD

UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep · Source last updated 2025-07-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percent of participants
Interval / dispersion
95% Confidence Interval
Time frame
Day 100

What was measured

Percentage of patients with grade III-IV acute GVHD.

Groups in this outcome

No Anti-thymocyte Globulin (ATG)

Hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycles of multi-agent chemotherapy within the 3 months previous to umbilical cord blood transplantation.

Anti-thymocyte Globulin (ATG)

Hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplantation, should receive Anti-thymocyte Globulin (ATG) as part of their conditioning regimen.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
No Anti-thymocyte Globulin (ATG)5
Anti-thymocyte Globulin (ATG)10

Reported measurements

Source class 1
Values in Percent of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
No Anti-thymocyte Globulin (ATG)0Not reported0100Not reported
Anti-thymocyte Globulin (ATG)10Not reported028Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        100
        value
        0
      2. group Id
        OG001
        lower Limit
        0
        upper Limit
        28
        value
        10
denoms
  1. counts
    1. group Id
      OG000
      value
      5
    2. group Id
      OG001
      value
      10
    units
    Participants
description
Percentage of patients with grade III-IV acute GVHD.
dispersion Type
95% Confidence Interval
groups
  1. description
    Hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycles of multi-agent chemotherapy within the 3 months previous to umbilical cord blood transplantation.
    id
    OG000
    title
    No Anti-thymocyte Globulin (ATG)
  2. description
    Hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplantation, should receive Anti-thymocyte Globulin (ATG) as part of their conditioning regimen.
    id
    OG001
    title
    Anti-thymocyte Globulin (ATG)
param Type
NUMBER
reporting Status
POSTED
time Frame
Day 100
title
Incidence of Acute GVHD
type
SECONDARY
unit Of Measure
Percent of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice